2008
Estimation of HIV Incidence in the United States
Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, Karon J, Brookmeyer R, Kaplan EH, McKenna MT, Janssen RS, Group F. Estimation of HIV Incidence in the United States. JAMA 2008, 300: 520-529. PMID: 18677024, PMCID: PMC2919237, DOI: 10.1001/jama.300.5.520.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHIV incidenceHIV infectionBED HIV-1 capture enzyme immunoassayIncidence of HIVNew infectionsPatients 13 yearsNew HIV infectionsPercent of infectionsClinic-based settingBlack individualsCapture enzyme immunoassayHIV diagnosisHIV casesImmunodeficiency virusRecent infectionIncidence rateMAIN OUTCOMEDiagnostic seraAIDS incidenceDisease controlInfectionEnzyme immunoassayIncidenceDiagnostic specimens
2001
Public Health Consequences of Screening Patients for Adherence to Highly Active Antiretroviral Therapy
Tchetgen E, Kaplan E, Friedland G. Public Health Consequences of Screening Patients for Adherence to Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 26: 118-129. DOI: 10.1097/00126334-200102010-00003.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyAntiretroviral therapyDrug resistanceDrug-resistant virusesNew HIV infectionsHIV antiretroviral therapyImportance of adherencePublic health consequencesHIV patientsHIV infectionTreatment regimensScreening patientsAIDS casesPatient benefitPhysician's abilityPatientsAIDS incidenceTherapyHealth consequencesAdherenceRecent studiesPopulation levelHAARTRegimensHIVPublic Health Consequences of Screening Patients for Adherence to Highly Active Antiretroviral Therapy
Tchetgen E, Kaplan E, Friedland G. Public Health Consequences of Screening Patients for Adherence to Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 26: 118-129. PMID: 11242178, DOI: 10.1097/00042560-200102010-00003.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyAntiretroviral therapyDrug resistanceDrug-resistant virusesNew HIV infectionsHIV antiretroviral therapyImportance of adherencePublic health consequencesHIV patientsHIV infectionTreatment regimensScreening patientsAIDS casesPatient benefitPhysician's abilityPatientsAIDS incidenceTherapyHealth consequencesAdherenceRecent studiesPopulation levelHAARTRegimensHIV
1994
A method for evaluating needle exchange programmes
Kaplan E. A method for evaluating needle exchange programmes. Statistics In Medicine 1994, 13: 2179-2187. PMID: 7846418, DOI: 10.1002/sim.4780131923.Peer-Reviewed Original Research
1992
R0 bounds for worst-case endemic mixing models
Kaplan E. R0 bounds for worst-case endemic mixing models. Mathematical Biosciences 1992, 110: 131-132. PMID: 1623294, DOI: 10.1016/0025-5564(92)90019-s.Peer-Reviewed Original ResearchHIV prevalence among intravenous drug users: model-based estimates from New Haven's legal needle exchange.
Kaplan E, Heimer R. HIV prevalence among intravenous drug users: model-based estimates from New Haven's legal needle exchange. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1992, 5: 163-9. PMID: 1732509.Peer-Reviewed Original ResearchMeSH KeywordsConnecticutHealth PolicyHIV InfectionsHumansModels, StatisticalNeedle SharingPrevalenceProgram EvaluationSubstance Abuse, IntravenousConceptsIntravenous drug users
1991
Mean-max bounds for worst-case endemic mixing models
Kaplan E. Mean-max bounds for worst-case endemic mixing models. Mathematical Biosciences 1991, 105: 97-109. PMID: 1806097, DOI: 10.1016/0025-5564(91)90050-s.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeEpidemiologic MethodsHIV InfectionsHumansMathematicsModels, StatisticalMortality